The DOI matches its Crossref record.
Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A different mechanism is demonstrated by the macrolide antibiotic approved by the FDA for the treatment of Clostridioides difficile infections, fidaxomicin, which inhibits DNA-dependent RNA polymerase [102].”
From Molecular Mechanisms of Drug Resistance in Staphylococcus aureus (2022) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 33
- Bartlett, 1984, Disease-a-month : DM, 30, 1
- 2005, New England Journal of Medicine, 353, 2442, 10.1056/NEJMoa051639 · DOI · Paper page
- 2005, New England Journal of Medicine, 353, 2433, 10.1056/NEJMoa051590 · DOI · Paper page
- Pepin, 2004, Canadian Medical Association Journal, 171, 466, 10.1503/cmaj.1041104 · DOI · Paper page
- 2010, INFECT CONT HOSP EP, 31, 431, 10.1086/651706 · DOI · Paper page
- 2007, Clinical Infectious Diseases, 45, 302, 10.1086/519265 · DOI · Paper page
- 1997, Clinical Infectious Diseases, 24, 324, 10.1093/clinids/24.3.324 · DOI · Paper page
- Teasley, 1983, Lancet, 2, 1043, 10.1016/S0140-6736(83)91036-X · DOI · Paper page
- 2006, Clinical Infectious Diseases, 42, 758, 10.1086/501126 · DOI · Paper page
- 2009, Antimicrobial Agents and Chemotherapy, 53, 223, 10.1128/AAC.01442-07 · DOI
- 2008, Antimicrobial Agents and Chemotherapy, 52, 1391, 10.1128/AAC.01045-07 · DOI
- Chopra, 2007, Current opinion in investigational drugs (London, England : 2000), 8, 600
- Coronelli, 1975, The Journal of antibiotics, 28, 253, 10.7164/antibiotics.28.253 · DOI
- Gualtieri, 2006, Antimicrobial Agents and Chemotherapy, 50, 401, 10.1128/AAC.50.1.401-402.2006 · doi:10.1128/aac.50.1.401-402.2006
- Swanson, 1991, Antimicrobial Agents and Chemotherapy, 35, 1108, 10.1128/AAC.35.6.1108 · DOI
- Miller, 2010, Expert opinion on pharmacotherapy, 11, 1569, 10.1517/14656566.2010.485614 · DOI
- Sergio, 1975, The Journal of antibiotics, 28, 543, 10.7164/antibiotics.28.543 · DOI
- Louie, 2011, New England Journal of Medicine, 364, 422, 10.1056/NEJMoa0910812 · DOI · Paper page
- Credito, 2004, Antimicrobial Agents and Chemotherapy, 48, 4430, 10.1128/AAC.48.11.4430-4434.2004 · DOI
- Finegold, 2004, Antimicrobial Agents and Chemotherapy, 48, 4898, 10.1128/AAC.48.12.4898-4902.2004 · DOI
- Theriault, 1987, The Journal of antibiotics, 40, 567, 10.7164/antibiotics.40.567 · DOI
- 2009, Antimicrobial Agents and Chemotherapy, 53, 261, 10.1128/AAC.01443-07 · DOI · Paper page
- 2010, Microbiology, 156, 3354, 10.1099/mic.0.042010-0 · DOI · Paper page
- Ackermann, 2004, Antimicrobial Agents and Chemotherapy, 48, 2280, 10.1128/AAC.48.6.2280-2282.2004 · DOI
- 2007, Antimicrobial Agents and Chemotherapy, 51, 2716, 10.1128/AAC.01623-06 · DOI · Paper page
- 2008, Antimicrobial Agents and Chemotherapy, 52, 4163, 10.1128/AAC.00476-08 · DOI
- Citron, 2009, 15, 234, 10.1016/j.anaerobe.2009.09.005 · doi:10.1016/j.anaerobe.2009.09.005
- 2011, Antimicrobial Agents and Chemotherapy, 55, 5194, 10.1128/AAC.00625-11 · doi:10.1128/aac.00625-11
- 2011, Journal of Medical Microbiology, 60, 1213, 10.1099/jmm.0.029470-0 · DOI
- 2008, J ANTIMICROB CH, 62, 713, 10.1093/jac/dkn269 · DOI
- 2011, Antimicrobial Agents and Chemotherapy, 55, 4427, 10.1128/AAC.00104-11 · DOI
- 2008, Antimicrobial Agents and Chemotherapy, 52, 2813, 10.1128/AAC.00342-08 · DOI · Paper page
- 2011, Clinical Infectious Diseases, 53, 440, 10.1093/cid/cir404 · DOI · Paper page
Cited by
Clostridium difficile colitis: pathogenesis and host defence
Abt, M. C., McKenney, P. T., & Pamer, E. G. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.108 · Cited by 551
Molecular Mechanisms of Drug Resistance in Staphylococcus aureus
Mlynarczyk-Bonikowska, B., Kowalewski, C., Krolak-Ulinska, A., & Marusza, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158088 · Cited by 412
Prospects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 372
Al-Worafi, Y. M. (2020) · Drug Safety in Developing Countries · doi:10.1016/b978-0-12-819837-7.00008-x · Cited by 371
Dhingra, S., Rahman, N. A. A., Peile, E., Rahman, M., Sartelli, M., Hassali, M. A., Islam, T., Islam, S., & Haque, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.535668 · Cited by 329
Metadata
- Authors
- Venugopal, A. A., & Johnson, S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-12-07
- Volume
- 54
- Issue
- 4
- Pages
- 568-574
- ISSN
- 1058-4838
- 1537-6591
- Cited by
- 135
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection. https://app.cochat.ai/papers/10.1093/cid/cir830
- The paper
- Venugopal, A. A., & Johnson, S. (2012). Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection. Clinical Infectious Diseases. https://doi.org/10.1093/cid/cir830
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.